Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on July 29, 2020. The report details corporate governance changes, specifically the election of new members to the Board of Directors effective September 1, 2020.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on director appointments and associated compensation arrangements.
Material Changes
The Board of Directors increased its size to fourteen members. Two new directors were elected:
- Ms. Paula A. Price: Former EVP and CFO of Macy's, Inc., with extensive financial and operational experience.
- Mr. Derica W. Rice: Former EVP of CVS Health and President of CVS Caremark, with a 27-year tenure at Eli Lilly and Company.
Both directors were determined to be independent under NYSE Listing Standards.
Guidance, Outlook, and Compensation
The filing does not provide financial guidance, outlook, or management commentary on business risks. However, it outlines the compensatory arrangements for the new directors:
- Annual retainer: $100,000.
- Annual award of deferred share units: Valued at $185,000 on the date of grant.
No related party transactions or special understandings regarding their selection were disclosed.
Investor Verification Checklist
- Confirm the effective date of the new directors' service (September 1, 2020).
- Verify the total Board size is now fourteen members.
- Review the attached press release (Exhibit 99.1) for additional context on the appointments.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial data.